MARKET

NARI

NARI

Inari Medical, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

68.00
+0.03
+0.04%
After Hours: 68.00 0 0.00% 16:00 11/23 EST
OPEN
68.55
PREV CLOSE
67.97
HIGH
69.10
LOW
67.15
VOLUME
827.16K
TURNOVER
--
52 WEEK HIGH
84.91
52 WEEK LOW
39.55
MARKET CAP
3.13B
P/E (TTM)
1178.51
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Abbott Labs, Intuitive Surgical Headline 5 Top Stocks Near Buy Points
Investor's Business Daily · 11/14 13:00
Inari Medical Highlights Presentation Of Positive 30-Day Follow-Up Results From First Patients In Real World FLASH Registry
Inari Medical, Inc. (NASDAQ:NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today
Benzinga · 11/13 15:02
Morgan Stanley Maintains Overweight on Inari Medical, Raises Price Target to $85
Morgan Stanley maintains Inari Medical (NASDAQ:NARI) with a Overweight and raises the price target from $76 to $85.
Benzinga · 11/13 12:55
Inari Medical EPS beats by $0.18, beats on revenue
Inari Medical (NARI): Q3 GAAP EPS of $0.12 beats by $0.18.Revenue of $38.72M (+172.1% Y/Y) beats by $12.19M.Cash and equivalents were $168M, which reflects a $30.3M payoff of our long-term
Seekingalpha · 11/12 21:26
Inari Medical Q3 EPS $0.12 Beats $(0.04) Estimate, Sales $38.70M Beat $26.53M Estimate
Inari Medical (NASDAQ:NARI) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $(0.04) by 400 percent. The company reported quarterly sales of $38.70 million which beat the
Benzinga · 11/12 21:06
Inari Medical Appoints Kevin Strange as VP of Strategy and Business Development and Angela Ahmad as General Counsel
IRVINE, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the appointment of Kevin Strange as VP of Strategy and Business Development, and Angela Ahmad as General Counsel. In his role, Mr. Strange will be responsible for Inari’s corporate strategy and business development initiatives. Ms. Ahmad has over 20 years of corporate and securities experience and will oversee all aspects of the Company’s legal activities in her role. “We could not be more excited for Kevin and Angela to join us.  Kevin comes to us with deep experience not only in strategy and business development, but also in the peripheral vascular space more broadly.  He will be highly valuable as we explore opportunities to address important unmet needs in the venous space and immediate adjacencies,” said Bill Hoffman, Chairman and CEO. “Angela brings to the company deep experience advising publicly listed companies on legal matters and she will be an invaluable asset. We eagerly welcome her guidance and counsel as part of our leadership team.”Mr. Strange joins Inari with over 15 years of medical device experience, most recently serving as the Director of Business Development for the Peripheral Interventions division of Boston Scientific where he led multiple acquisition, divestiture and venture capital transactions. Prior to joining Boston Scientific, Mr. Strange was an equity research analyst at Bank of America Merrill Lynch and Wells Fargo Securities covering the Medical Supplies & Devices sector. He began his career in the medical device field in clinical support and sales roles at Medtronic.Prior to joining Inari, Ms. Ahmad served as Deputy General Counsel of CoreLogic, Inc., where she held various roles including overseeing the corporate governance, M&A and securities functions. Prior to CoreLogic, Ms. Ahmad served as an associate at Latham & Watkins, LLP, where she advised clients on corporate transactions, including equity and debt financings. Ms. Ahmad has significant international legal experience, having spent five years in London, England with Latham & Watkins and Fried Frank.About Inari Medical, Inc. Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases.Inari is focused on treating venous thromboembolism and improving the quality of life of patients suffering from this disease by safely and effectively removing blood clots. Inari has developed two minimally invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The ClotTriever system is 510(k)-cleared by the FDA for thrombectomy in the peripheral vessels and is used to treat patients suffering from deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA for the treatment of pulmonary embolism.Forward Looking Statements Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements are based on Inari’s current expectations, forecasts and assumptions, are subject to inherent uncertainties, risks and assumptions that are difficult to predict and actual outcomes and results could differ materially due to a number of factors. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Quarterly Report on Form 10-Q for the period ended June 30, 2020 and in its other reports filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are based on information available to Inari as of the date hereof and are made only as of the date of this release. Inari undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing Inari’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Inari.Investor Contact: Westwicke Partners Caroline Corner Phone +1-415-202-5678 caroline.corner@westwicke.com
GlobeNewswire · 11/12 21:01
Inari Medical Inc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Inari Medical Inc (NARI) (NASDAQ:NARI)will be discussing their earnings results in their call to be held on November 12, 2020 at 4:30 PM Eastern Time.
ACCESSWIRE · 11/12 19:30
Is Inari Medical, Inc.'s (NASDAQ:NARI) ROE Of 0.6% Concerning?
Simply Wall St. · 11/12 12:41
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NARI. Analyze the recent business situations of Inari Medical, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NARI stock price target is 85.17 with a high estimate of 94.00 and a low estimate of 70.00.
EPS
Institutional Holdings
Institutions: 126
Institutional Holdings: 8.65M
% Owned: 18.78%
Shares Outstanding: 46.08M
TypeInstitutionsShares
Increased
25
2.13M
New
75
299.52K
Decreased
16
1.17M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.12%
Healthcare Equipment & Supplies
-0.37%
Key Executives
Non-Executive Chairman/Independent Director
Donald Milder
Chief Executive Officer/Primary Contact
Bill Hoffman
President/Chief Executive Officer/Director
William Hoffman
Chief Financial Officer
Mitchell Hill
Chief Operating Officer
Andrew Hykes
Other
Thomas Tu
Independent Director
Cynthia Lucchese
Independent Director
Kirk Nielsen
Independent Director
Geoff Pardo
Independent Director
Jonathan Root
Independent Director
Catherine Szyman
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NARI
Inari Medical, Inc. is a commercial-stage medical device company. The Company is focused on developing products to treat venous diseases. The Company’s product offering consists of two minimally-invasive, catheter-based mechanical thrombectomy devices. The Company built two products for the treatment of venous thromboembolism (VTE deep vein thrombosis) and pulmonary embolism (PE). The Company provides two products ClotTriever and FlowTriever. ClotTriever product is Food and Drug Administration (FDA) cleared for the removal of clot from peripheral blood vessels and is used to deep vein thrombosis (DVT). FlowTriever product is thrombectomy system FDA cleared for the treatment of pulmonary embolism (PE). Its product ClotTriever and FlowTriever offer clinical benefits and provides safety to limit effectiveness of thrombolytic drugs and repurposed arterial devices for the treatment of VTE.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Inari Medical Inc stock information, including NASDAQ:NARI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NARI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NARI stock methods without spending real money on the virtual paper trading platform.